Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TM-Alliance study of TM5614 with chemoradiotherapy and immune checkpoint inhibitor consolidation in locally advanced NSCLC
jRCT2061260001Phase 2Recruiting
- Start
- Jul 2026
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TM5614 in non-small cell lung cancer (NSCLC), sponsored by none. Primary endpoint: 1-year progression-free survival rate. Started Jul 2026; status: recruiting.
02
Drugs
TM5614
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2061260001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061260001.